Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

Discover a study that raises important concerns about the long-term mental health of individuals with resolved HBV infection.

Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...

Net Loss: For the first quarter of 2025, the Company generated a net loss attributable to its shareholders of $19.6 million, ...